cting via Winsock to STN

Welcome to STN International!  Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | AUG 10 | Time limit for inactive STN sessions doubles to 40 minutes |
| NEWS 3 | AUG 18 | COMPENDEX indexing changed for the Corporate Source (CS) field |
| NEWS 4 | AUG 24 | ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced |
| NEWS 5 | AUG 24 | CA/CAplus enhanced with legal status information for U.S. patents |
| NEWS 6 | SEP 09 | 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY |
| NEWS 7 | SEP 11 | WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus |
| NEWS 8 | OCT 21 | Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded |
| NEWS 9 | OCT 21 | Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models |
| NEWS 10 | NOV 23 | Addition of SCAN format to selected STN databases |
| NEWS 11 | NOV 23 | Annual Reload of IFI Databases |
| NEWS 12 | DEC 01 | FRFULL Content and Search Enhancements |
| NEWS 13 | DEC 01 | DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets |
| NEWS 14 | DEC 02 | Derwent World Patent Index: Japanese FI-TERM thesaurus added |
| NEWS 15 | DEC 02 | PCTGEN enhanced with patent family and legal status display data from INPADOCDB |
| NEWS 16 | DEC 02 | USGENE: Enhanced coverage of bibliographic and sequence information |
| NEWS 17 | DEC 21 | New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus |
| NEWS 18 | JAN 12 | Match STN Content and Features to Your Information Needs, Quickly and Conveniently |
| NEWS 19 | JAN 25 | Annual Reload of MEDLINE database |

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS  STN Operating Hours Plus Help Desk Availability
NEWS LOGIN  Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement.  This agreement limits use to scientific research.  Use

for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:40:13 ON 01 FEB 2010

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.66 0.66

FILE 'CAPLUS' ENTERED AT 15:41:58 ON 01 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Feb 2010 VOL 152 ISS 6
FILE LAST UPDATED: 31 Jan 2010 (20100131/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s aripiprazole
L1 1149 ARIPIPRAZOLE

=> s l1 and dehydroaripiprazole
17 DEHYDROARIPIPRAZOLE
L2 17 L1 AND DEHYDROARIPIPRAZOLE

=> s l2 and @py<2003
'2003' NOT A VALID FIELD CODE
0 @PY<2003
L3 0 L2 AND @PY<2003

=> s l2 and @py<2004
'2004' NOT A VALID FIELD CODE
0 @PY<2004
L4 0 L2 AND @PY<2004

```
=> s l2 and py<2003
      22999133 PY<2003
L5            0 L2 AND PY<2003

=> s l2 and py<2005
      25158458 PY<2005
L6            2 L2 AND PY<2005

=> d l6 1-2 ibib ab

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2004:1059117  CAPLUS
DOCUMENT NUMBER:          142:43770
TITLE:                    Carbostyril derivatives and mood stabilizers for
                          treating mood disorders
INVENTOR(S):              Kikuchi, Tetsuro; Iwamoto, Taro; Hirose, Tsuyoshi
PATENT ASSIGNEE(S):       Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 81 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2004105682         A2    20041209    WO 2004-US13308         20040519 <--
     WO 2004105682         A3    20050512
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004243096         A1    20041209    AU 2004-243096          20040519 <--
     AU 2004243096         B2    20081218
     CA 2526562            A1    20041209    CA 2004-2526562         20040519 <--
     EP 1626721            A2    20060222    EP 2004-785621          20040519
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     BR 2004010786         A     20060620    BR 2004-10786           20040519
     CN 1794994            A     20060628    CN 2004-80014103        20040519
     JP 2007503460         T     20070222    JP 2006-532509          20040519
     ZA 2005008306         A     20070328    ZA 2005-8306            20040519
     NZ 542985             A     20090430    NZ 2004-542985          20040519
     RU 2359675            C2    20090627    RU 2005-140285          20040519
     NO 2005005152         A     20051207    NO 2005-5152            20051103
     MX 2005012538         A     20060222    MX 2005-12538           20051121
     KR 2006021857         A     20060308    KR 2005-722168          20051121
     KR 881046             B1    20090130
     IN 2005KN02340        A     20070706    IN 2005-KN2340          20051122
     US 20070031513        A1    20070208    US 2006-556600          20060802
PRIORITY APPLN. INFO.:                       US 2003-473378P     P   20030523
                                             WO 2004-US13308     W   20040519
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
```

AB The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotrigine, topiramate, gabapentin, levetiracetam or clonazepam. These compns. are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for sep. administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder. Thus, a formulation contained dehydroaripiprazole 5, clonazepam 600, starch 131, Mg stearate 4, and lactose 60 mg.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:996135 CAPLUS

DOCUMENT NUMBER: 141:424212

TITLE: Process for the preparation of carbostyril derivatives such as aripiprazole via reaction of dichlorophenylpiperazine to give a quaternary ammonium spiro intermediate.

INVENTOR(S): Salama, Paul; Meunier, Jean-Francois; Lafreniere, Julie; Wang, Yuan; Liu, Lu Wei

PATENT ASSIGNEE(S): Delmar Chemicals Inc., Can.

SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004099152 | A1 | 20041118 | WO 2004-CA605 | 20040423 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2428237 | A1 | 20041108 | CA 2003-2428237 | 20030508 <-- |
| EP 1625116 | A1 | 20060215 | EP 2004-729020 | 20040423 |
| EP 1625116 | B1 | 20070808 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1784385 | A | 20060607 | CN 2004-80012474 | 20040423 |
| AT 369343 | T | 20070815 | AT 2004-729020 | 20040423 |
| PT 1625116 | E | 20070827 | PT 2004-729020 | 20040423 |
| ES 2290698 | T3 | 20080216 | ES 2004-729020 | 20040423 |
| US 20070032651 | A1 | 20070208 | US 2005-555485 | 20051103 |
| IN 2005DN05130 | A | 20071207 | IN 2005-DN5130 | 20051109 |

PRIORITY APPLN. INFO.: CA 2003-2428237 A 20030508

```
                                        WO 2004-CA605       W  20040423
                                        CA 2005-2428237     A  20050508
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):         CASREACT 141:424212; MARPAT 141:424212
AB   A process for preparation of carbostyril derivs. comprises reaction of
     dichlorophenylpiperazine or an acid addition salt thereof with XC4H8Y or
     XC4H6Y (X, Y = leaving groups) to produce novel quaternary spiro ammonium
     salt intermediates (I; dotted line = optional double bond) and reaction of
     the latter with 7-hydroxydihydrocarbostyril to give title compds. (II; n =
     6, 8).  Thus, 1-(2,3-dichlorophenyl)piperazine hydrochloride, Br(CH2)4Br,
     and K2CO3 were refluxed 15 h in acetone to give 85%
     8-(2,3-dichlorophenyl)-8-aza-5-azoniaspiro[4,5]decane bromide.  This was
     refluxed 18 h with 7-hydroxy-4,5-dihydrocarbostyryl in Me iso-Bu
     ketone/DMF to give aripiprazole.
OS.CITING REF COUNT:     2     THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
                               (2 CITINGS)
REFERENCE COUNT:         4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> dehydroaripiprazole
DEHYDROARIPIPRAZOLE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s dehydroaripiprazole
L7          17 DEHYDROARIPIPRAZOLE

=> s l7 and py<2003
      22999133 PY<2003
L8           0 L7 AND PY<2003

=> s aripiprazole and depression
          1149 ARIPIPRAZOLE
         97650 DEPRESSION
          8458 DEPRESSIONS
        104170 DEPRESSION
                  (DEPRESSION OR DEPRESSIONS)
L9          186 ARIPIPRAZOLE AND DEPRESSION

=> s l9 and py<2003
      22999133 PY<2003
L10          5 L9 AND PY<2003

=> d l10 1-5 ibib ab

L10  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:        2002:977588  CAPLUS
DOCUMENT NUMBER:         138:33362
TITLE:                   Use of cyclooxygenase 2 (COX-2) inhibitors for the
                         treatment of schizophrenia, delusional disorders,
                         affective disorders, autism, or tic disorders
INVENTOR(S):             Muller, Norbert
PATENT ASSIGNEE(S):      Germany
SOURCE:                  PCT Int. Appl., 58 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  3
PATENT INFORMATION:
```

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002102297 | A2 | 20021227 | WO 2002-EP6013 | 20020531 <-- |
| WO 2002102297 | A3 | 20030501 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10129320 | A1 | 20030410 | DE 2001-10129320 | 20010619 |
| CA 2448025 | A1 | 20021227 | CA 2002-2448025 | 20020531 <-- |
| AU 2002312967 | A1 | 20030102 | AU 2002-312967 | 20020531 |
| EP 1397145 | A2 | 20040317 | EP 2002-738138 | 20020531 |
| EP 1397145 | B1 | 20060906 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004534066 | T | 20041111 | JP 2003-504886 | 20020531 |
| JP 4205577 | B2 | 20090107 | | |
| EP 1627639 | A2 | 20060222 | EP 2005-24864 | 20020531 |
| EP 1627639 | A3 | 20060927 | | |
| EP 1627639 | B1 | 20091223 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| AP 1512 | A | 20060228 | AP 2003-2934 | 20020531 |
| W: BW, GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW | | | | |
| AT 338557 | T | 20060915 | AT 2002-738138 | 20020531 |
| PT 1397145 | E | 20061031 | PT 2002-738138 | 20020531 |
| ES 2271269 | T3 | 20070416 | ES 2002-738138 | 20020531 |
| US 20040204469 | A1 | 20041014 | US 2004-480600 | 20040205 |
| JP 2008297308 | A | 20081211 | JP 2008-188890 | 20080722 |

| PRIORITY APPLN. INFO.: | | | |
|---|---|---|---|
| DE 2001-10129320 | A | 20010619 | |
| US 2002-364904P | P | 20020314 | |
| EP 2002-738138 | A3 | 20020531 | |
| JP 2003-504886 | A3 | 20020531 | |
| WO 2002-EP6013 | W | 20020531 | |

OTHER SOURCE(S): MARPAT 138:33362

AB The invention discloses the use of a COX-2 inhibitor for the treatment of psychiatric disorders, e.g. schizophrenia, delusional disorders, affective disorders, autism or tic disorders, in particular chronic schizophrenic psychoses and schizoaffective psychoses, temporary acute psychotic disorders, depressive episodes, recurring depressive episodes, manic episodes and bipolar affective disorders. Moreover, the invention discloses the use of a COX-2 inhibitor, in particular celecoxib, in combination with a neuroleptic drug, in particular risperidone, or an antidepressant, for the treatment of psychiatric disorders such as schizophrenia, delusional disorders, affective disorders, autism or tic disorders.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:889556 CAPLUS

DOCUMENT NUMBER: 137:363096

TITLE: Carbostyril derivative 5-HT1a receptor subtype agonist for treatment of central nervous system disorders
INVENTOR(S): Jordan, Shaun; Kikuchi, Tetsuro; Tottori, Katsura; Hirose, Tsuyoshi; Uwahodo, Yasufumi
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| US 20020173513 | A1 | 20021121 | US 2002-55915 | | 20020128 <-- |
| US 7053092 | B2 | 20060530 | | | |
| US 20040235860 | A1 | 20041125 | US 2004-876605 | | 20040628 |
| US 20080171752 | A1 | 20080717 | US 2007-932795 | | 20071031 |
| US 20080318972 | A1 | 20081225 | US 2008-202208 | | 20080829 |
| US 20090012098 | A1 | 20090108 | US 2008-202201 | | 20080829 |
| US 20090181978 | A1 | 20090716 | US 2008-202192 | | 20080829 |
| PRIORITY APPLN. INFO.: | | | US 2001-331370P | P | 20010129 |
| | | | US 2002-55915 | A3 | 20020128 |
| | | | US 2004-876605 | A3 | 20040628 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention provides a method for treating a patient suffering from a disorder of the central nervous system associated with the 5-HT1a receptor subtype, comprising as an active ingredient a carbostyril derivative I (carbon-carbon bond between 3- and 4-positions in carbostyril skeleton is single or double bond), or a salt thereof.
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:521465 CAPLUS
DOCUMENT NUMBER: 137:98994
TITLE: Pharmaceuticals containing a combination of norepinephrine reuptake inhibitors and neuroleptics
INVENTOR(S): Wong, Erik Ho Fong; Gallen, Christopher C.; Svensson, Torgny
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA; Pharmacia AB
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002053140 | A2 | 20020711 | WO 2001-US45871 | 20011227 <-- |
| WO 2002053140 | A3 | 20021024 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| CA 2431041 | A1 | 20020711 | CA 2001-2431041 | | 20011227 <-- |
| AU 2002232470 | A1 | 20020716 | AU 2002-232470 | | 20011227 <-- |
| AU 2002232470 | B2 | 20051103 | | | |
| EP 1353675 | A2 | 20031022 | EP 2001-991997 | | 20011227 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2004517112 | T | 20040610 | JP 2002-554091 | | 20011227 |
| NZ 526801 | A | 20050729 | NZ 2001-526801 | | 20011227 |
| US 20020156067 | A1 | 20021024 | US 2001-35100 | | 20011228 <-- |
| US 6964962 | B2 | 20051115 | | | |
| MX 2003006003 | A | 20050908 | MX 2003-6003 | | 20030702 |
| US 20060003992 | A1 | 20060105 | US 2005-219901 | | 20050906 |
| PRIORITY APPLN. INFO.: | | | US 2001-259286P | P | 20010102 |
| | | | WO 2001-US45871 | W | 20011227 |
| | | | US 2001-35100 | A3 | 20011228 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A composition comprising: (a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a salt; and (b) 1 or more neuroleptics is provided. The composition is useful in treating disorders or diseases of the central nervous system, and particularly useful in treating schizophrenia. A pharmaceutical composition was prepared by combining reboxetine with a neuroleptic in an acceptable carrier. The composition contains 0.01-10 mg rebexetine and 25-300 mg clozapine.

OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:440186 CAPLUS

DOCUMENT NUMBER: 138:83213

TITLE: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

AUTHOR(S): Jordan, Shaun; Koprivica, Vuk; Chen, Ruoyan; Tottori, Katsura; Kikuchi, Tetsuro; Altar, C. Anthony

CORPORATE SOURCE: Maryland Research Laboratories, Neuroscience Department, Otsuka Maryland Research Institute, Rockville, MD, 20850, USA

SOURCE: European Journal of Pharmacology (2002), 441(3), 137-140
CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Aripiprazole, 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone, a novel antipsychotic with partial agonist activity at dopamine D2 receptors, bound with high affinity to recombinant human 5-HT1A receptors (h5-HT1A) in Chinese hamster ovary cell membranes and displayed potent, partial agonism at 5-HT1A receptors in a guanosine-5'-O-(3-[35S]thio)-triphosphate ([35S]GTPγS)-binding assay that was blocked completely by a selective 5-HT1A receptor antagonist. An interaction with 5-HT1A receptors may contribute to the overall efficacy of aripiprazole against symptoms of schizophrenia, including anxiety, depression , cognitive and neg. symptoms, and to its favorable side-effect profile. Combined with previous studies demonstrating the potent partial agonism of aripiprazole at dopamine D2 receptors, this study suggests aripiprazole is the first dopamine-serotonin system stabilizer.

OS.CITING REF COUNT: 168 THERE ARE 168 CAPLUS RECORDS THAT CITE THIS RECORD (168 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:419712 CAPLUS
DOCUMENT NUMBER: 137:27724
TITLE: Advances in atypical antipsychotics for the treatment of schizophrenia. New formulations and new agents
AUTHOR(S): Kelleher, James P.; Centorrino, Franca; Albert, Matthew J.; Baldessarini, Ross J.
CORPORATE SOURCE: Department of Psychiatry, Harvard Medical School, Boston, MA, USA
SOURCE: CNS Drugs (2002), 16(4), 249-261
CODEN: CNDREF; ISSN: 1172-7047
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Innovation in atypical antipsychotic agents continues with new prepns. of available drugs as well as novel agents. In this article, we provide an update on these novel products by reviewing information from a computerized literature search, recent abstrs. and discussions with industry representatives. A generic formulation of clozapine is now available. It may be less well absorbed and/or less effective than Clozaril, although evidence is conflicting. A fatty acid amide derivative of clozapine is in early development. A liquid formulation of risperidone is currently available, which may be a useful treatment for psychotic agitation as well as a preferable alternative to tablets for some patients. A depot formulation is in development for the long-term management of psychosis. An orally disintegrating tablet formulation of olanzepine is a useful alternative to standard tablets. A short-acting injectable formulation of the drug is in development for psychotic agitation. Sachets and slow-release formulations of quetiapine are in development. Ziprasidone, a recently launched agent, is available in tablet form for schizophrenia/schizoaffective disorder, psychotic depression and mania. A short-acting injectable formulation is in development for psychotic agitation. Aripiprazole (tablets) and iloperidone (tablets and depot injection) are two antipsychotics in development for schizophrenia/schizoaffective disorder (available information regarding iloperidone is very limited). These new formulations and agents should broaden options for the treatment of psychosis.
OS.CITING REF COUNT: 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 50.49 | 51.15 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -5.95 | -5.95 |

FILE 'STNGUIDE' ENTERED AT 15:51:37 ON 01 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jan 28, 2010 (20100128/UP).